- Previous Close
8.92 - Open
9.10 - Bid 8.91 x --
- Ask 8.92 x --
- Day's Range
8.86 - 9.26 - 52 Week Range
6.56 - 11.54 - Volume
11,857,683 - Avg. Volume
20,163,064 - Market Cap (intraday)
3.417B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
74.33 - EPS (TTM)
0.12 - Earnings Date --
- Forward Dividend & Yield 0.01 (0.11%)
- Ex-Dividend Date May 27, 2024
- 1y Target Est
--
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. It offers pre-clinical research, clinical research, and other consulting services. The company also provides clinical drug production, product test, pilot test scale-up, process verification batch production, and drug registration and approval services. In addition, it engages in the screening, evaluation, verification, and trading of phased technological achievements formed in the process of new drug research and development. The company was formerly known as Guangzhou Boji Medical & Biotechnological Co., Ltd. and changed its name to Boji Medical Technology Co.,Ltd. in September 2021. Boji Medical Technology Co.,Ltd. was founded in 1998 is headquartered in Guangzhou, China.
www.bojicro.comRecent News: 300404.SZ
View MorePerformance Overview: 300404.SZ
Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300404.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300404.SZ
View MoreValuation Measures
Market Cap
3.42B
Enterprise Value
3.21B
Trailing P/E
76.57
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.50
Price/Book (mrq)
3.47
Enterprise Value/Revenue
4.26
Enterprise Value/EBITDA
92.52
Financial Highlights
Profitability and Income Statement
Profit Margin
5.92%
Return on Assets (ttm)
0.70%
Return on Equity (ttm)
4.93%
Revenue (ttm)
753.2M
Net Income Avi to Common (ttm)
44.59M
Diluted EPS (ttm)
0.12
Balance Sheet and Cash Flow
Total Cash (mrq)
281.73M
Total Debt/Equity (mrq)
7.13%
Levered Free Cash Flow (ttm)
-16.51M